Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023)
| Date | 20 November 2023 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Central Division - Section |
| Type of action | Revocation Action |
| Case number(s) | UPC_CFI_80/2023 |
| Registry reference | ORD_579547/2023 · UPC_CFI_80/2023 |
| Parties | ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE v. HELIOS K.K, OSAKA UNIVERSITY |
Official decision (PDF) · UPC registry entry
Case timeline
- 11 October 2023 : Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_80/2023, 11 October 2023) ORD_579545/2023 · UPC_CFI_80/2023
- 17 November 2023 : Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 November 2023) ORD_584830/2023 · UPC_CFI_80/2023
- 18 March 2024 : Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024) ACT_465342/2023 · ORD_598256/2023 · UPC_CFI_80/2023
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 20 November 2023 (UPC_CFI_80/2023, ACT_465342/2023, App_577540/2023), panel 1 of the Munich Central Division (U. Voß, presiding, A. Kupecz, judge-rapporteur, P. Gerli, technically qualified judge) rejected the request of Healios K.K and Osaka University, proprietors of EP 3 056 564, to stay the revocation action brought by Astellas Institute for Regenerative Medicine pending the EPO opposition, in which the Opposition Division hearing is set for 4 March 2024. Leave to appeal was granted.
Question
Does an Opposition Division decision expected shortly, but open to appeal, justify a stay under Art. 33(10) UPCA and Rule 295(a) RoP?
Decision
The « rapid » decision referred to in Art. 33(10) UPCA need not be the final EPO decision: any relevant decision expected rapidly may suffice, provided a concrete and near date is established. The panel doubts that a decision expected in just over three months is rapid, but assumes that it is. An appeal is highly likely, the defendants having given no undertaking not to appeal, and a final decision is expected around mid-2028. The claimant’s interest in early legal certainty outweighs the saving in costs. The risk of conflicting decisions does not make a stay proportionate at this stage. The action continues at least until the interim conference of 14 March 2024, the panel stating that it is minded to postpone the hearing or stay if the patent is revoked.
Key points for practice
- Practical point: an imminent Opposition Division hearing is not enough, the proprietor must show that a final decision is near or undertake not to appeal.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 33(8) and (10) and Art. 73(2)(b)(ii)
- Rules of Procedure
- Preamble points 2, 4, 5 and 8, Rules 220.2, 224.1(b), 295(a) and 296.3
- European Patent Convention
- Art. 106(1)
- Case law cited
- Edwards Lifesciences v Meril Italy, Paris Central Division, 13 November 2023
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Revocation action.
Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE10 decisions in the corpusFollow this party
- defendantOSAKA UNIVERSITY9 decisions in the corpusFollow this party
- defendantHELIOS K.K4 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
- 11 October 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_80/2023, 11 October 2023) Revocation Action · UPC_CFI_80/2023
Le mémoire en défense à l'action en nullité est réputé signifié à la demanderesse le 29 septembre 2023, le délai de réponse à la demande de sursis sera fixé par une ordonnance distincte.
- 17 November 2023 Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 November 2023) Revocation Action · UPC_CFI_80/2023
L'annexe confidentielle n'est accessible qu'aux représentants des défenderesses et à trois personnes physiques désignées, dont un conseil externe. Elle est soustraite à l'accès des tiers et l'appel est autorisé.
- 20 November 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023) Revocation Action · UPC_CFI_80/2023
- 18 March 2024 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024) Revocation Action · UPC_CFI_80/2023
Le document D21 est admis sous réserve d'une réponse de la défenderesse avant le 11 avril 2024, la valeur du litige est fixée à 4 000 000 euros et l'audience confirmée au 26 juin 2024.
What the record states
- Nature of the act
- Revocation Action
- Outcome (Dhenne Avocats summary)
- Le sursis à statuer sur l'action en nullité est refusé : une décision de la division d'opposition proche mais susceptible de recours n'emporte pas, à ce stade, une décision rapide justifiant la suspension, l'appel est autorisé.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 056 564mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 November 2023) cited in this record
- Edwards Lifesciences v Meril Italy (CFI, 13 November 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_80/2023, 11 October 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_465342/2023, 16 June 2023) cited in this record
- Toyota Motor Europe NV/SA v Neo Wireless (CFI, 25 April 2024) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 056 564 | Mentioned in the analysis (role not qualified) Also mentioned in 6 other decision(s): Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 23 Ju · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 Ma · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 N · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_C · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_ · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_ | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.